In May, Novavax signed a $1.2bn licensing agreement with Sanofi for its adjuvanted Covid-19 vaccine. The deal grants Sanofi global commercialisation rights to the vaccine except in countries such as India, South Korea, and Japan where Novavax already has existing partnerships in place.